Literature DB >> 7759720

Inhaled nitric oxide and hemodynamic evaluation of patients with pulmonary hypertension before transplantation.

I Adatia1, S Perry, M Landzberg, P Moore, J E Thompson, D L Wessel.   

Abstract

OBJECTIVES: We investigated the effect of inhaled nitric oxide and infused acetylcholine in patients with pulmonary hypertension undergoing cardiac catheterization before cardiopulmonary transplantation.
BACKGROUND: The fate of patients under consideration for transplantation of the heart or lungs, or both, is influenced by the evaluation of their pulmonary vascular reactivity.
METHODS: We evaluated 11 patients who were classified into two groups on the basis of mean left atrial pressure > 15 mm Hg (group I, n = 6) or < or = 15 mm Hg (group II, n = 5). All patients inhaled nitric oxide at 80 ppm. This was preceded by an infusion of 10(-6) mol/liter of acetylcholine in seven consecutive patients (n = 3 in group I, n = 4 in group II).
RESULTS: In group I, inhaled nitric oxide decreased pulmonary artery pressure from (mean +/- SE) 71 +/- 13 to 59 +/- 10 mm Hg (p < 0.05), pulmonary vascular resistance from 14.9 +/- 3.8 to 7.6 +/- 1.7 Um2 (p < 0.05) and intrapulmonary shunt fraction from 17.8 +/- 3.6% to 12.7 +/- 2.1% (p < 0.05). Left atrial pressure tended to increase from 27 +/- 4 to 32 +/- 5 mm Hg (p = 0.07). In group II pulmonary vascular resistance decreased in response to nitric oxide from 36.4 +/- 9.0 to 31.1 +/- 7.9 Um2 (p < 0.05). Cardiac index, systemic pressure and resistance did not change in either group. Seven patients who received acetylcholine had no significant alteration in pulmonary hemodynamic variables.
CONCLUSIONS: These preliminary observations suggest that nitric oxide is a potent pulmonary vasodilator with minimal systemic effects. It may be useful in discriminating patients needing combined heart and lung transplantation from those requiring exchange of the heart alone.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7759720     DOI: 10.1016/0735-1097(95)00048-9

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  14 in total

Review 1.  Inhaled nitric oxide and pulmonary vasoreactivity.

Authors:  M Aranda; R G Pearl
Journal:  J Clin Monit Comput       Date:  2000       Impact factor: 2.502

2.  A European survey of the use of inhaled nitric oxide in the ICU. Working Group on Inhaled NO in the ICU of the European Society of Intensive Care Medicine.

Authors:  S Beloucif; D Payen
Journal:  Intensive Care Med       Date:  1998-08       Impact factor: 17.440

Review 3.  Inhaled nitric oxide and related therapies.

Authors:  Frederick E Barr; Duncan Macrae
Journal:  Pediatr Crit Care Med       Date:  2010-03       Impact factor: 3.624

4.  Simplified pulmonary vasodilatory testing in the cardiac catheterization laboratory with nasal cannula nitric oxide.

Authors:  M Scheurer; V Bandisode; A M Atz
Journal:  Pediatr Cardiol       Date:  2006 Jan-Feb       Impact factor: 1.655

5.  Nitric oxide, oxygen, and prostacyclin in children with pulmonary hypertension.

Authors:  M I Turanlahti; P O Laitinen; S J Sarna; E Pesonen
Journal:  Heart       Date:  1998-02       Impact factor: 5.994

6.  Cardiac catheterization in children with pulmonary hypertensive vascular disease.

Authors:  Prashant Bobhate; Long Guo; Shreepal Jain; Richard Haugen; James Y Coe; Dominic Cave; Jennifer Rutledge; Ian Adatia
Journal:  Pediatr Cardiol       Date:  2015-01-11       Impact factor: 1.655

Review 7.  Pulmonary Hypertension.

Authors:  Peter Oishi; Jeffrey R Fineman
Journal:  Pediatr Crit Care Med       Date:  2016-08       Impact factor: 3.624

Review 8.  Inhaled nitric oxide therapy in neonates and children: reaching a European consensus.

Authors:  Duncan J Macrae; David Field; Jean-Christophe Mercier; Jens Møller; Tom Stiris; Paolo Biban; Paul Cornick; Allan Goldman; Sylvia Göthberg; Lars E Gustafsson; Jürg Hammer; Per-Arne Lönnqvist; Manuel Sanchez-Luna; Gunnar Sedin; Nim Subhedar
Journal:  Intensive Care Med       Date:  2004-01-13       Impact factor: 17.440

Review 9.  The role of the NO axis and its therapeutic implications in pulmonary arterial hypertension.

Authors:  Evangelos D Michelakis
Journal:  Heart Fail Rev       Date:  2003-01       Impact factor: 4.214

Review 10.  Etiology, diagnosis, and pharmacologic treatment of pediatric pulmonary hypertension.

Authors:  Robert Tulloh
Journal:  Paediatr Drugs       Date:  2009       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.